Differentiation of human dendritic cell subsets for immune tolerance induction

Deluce-Kakwata-Nkor, Nora; Lamendour, Lucille; Chabot, Valérie; Héraud, Audrey; Ivanović, Zoran; Halary, Franck; Dehaut, F.; Velge-Roussel, Florence

doi:10.1016/j.tracli.2017.08.002

Cited by 15 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T regs are induced by DCs, which are antigen-presenting cells with critical roles in the induction and regulation of immunity [25]. In particular, BDCA2 + and BDCA4 + pDCs exert tolerogenic functions when mediating T reg development and increasing T reg frequencies [26,27]. Our data showed that the percentages of mDC and pDC subsets and MFI analysis of BDCA1-4 did not differ between mTORI-and CNI-treated patients.…”

Section: Discussionmentioning

confidence: 60%

Everolimus-Induced Immune Effects after Heart Transplantation: A Possible Tool for Clinicians to Monitor Patients at Risk for Transplant Rejection

Klaeske

Lehmann

et al. 2021

Life

View full text Add to dashboard Cite

Background: Patients treated with an inhibitor of the mechanistic target of rapamycin (mTORI) in a calcineurin inhibitor (CNI)-free immunosuppressive regimen after heart transplantation (HTx) show a higher risk for transplant rejection. We developed an immunological monitoring tool that may improve the identification of mTORI-treated patients at risk for rejection. Methods: Circulating dendritic cells (DCs) and regulatory T cells (Tregs) were analysed in 19 mTORI- and 20 CNI-treated HTx patients by flow cytometry. Principal component and cluster analysis were used to identify patients at risk for transplant rejection. Results: The percentages of total Tregs (p = 0.02) and CD39+ Tregs (p = 0.05) were higher in mTORI-treated patients than in CNI-treated patients. The principal component analysis revealed that BDCA1+, BDCA2+ and BDCA4+ DCs as well as total Tregs could distinguish between non-rejecting and rejecting mTORI-treated patients. Most mTORI-treated rejectors showed higher levels of BDCA2+ and BDCA4+ plasmacytoid DCs and lower levels of BDCA1+ myeloid DCs and Tregs than mTORI non-rejectors. Conclusion: An mTORI-based immunosuppressive regimen induced a sufficient, tolerance-promoting reaction in Tregs, but an insufficient, adverse effect in DCs. On the basis of patient-specific immunological profiles, we established a flow cytometry-based monitoring tool that may be helpful in identifying patients at risk for rejection.

show abstract

Section: Discussionmentioning

confidence: 60%

Everolimus-Induced Immune Effects after Heart Transplantation: A Possible Tool for Clinicians to Monitor Patients at Risk for Transplant Rejection

Klaeske

Lehmann

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…Likewise, differentiation of immunosuppressive DC-SIGN+ DCs in prostate cancer tissue was orchestrated primarily by factors derived from adjacent stroma [ 40 ]. After stimulation with LPS, DC-SIGN+ DCs were shown to dramatically increase the secretion of pro-tolerant cytokine IL-10 [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Presence of Dendritic Cell Subsets in Sentinel Nodes of Breast Cancer Patients Is Related to Nodal Burden

Szpor

Streb

Glajcar

et al. 2022

IJMS

View full text Add to dashboard Cite

BACKGROUND: Sentinel lymph nodes (SLNs) are both the first site where breast cancer (BC) metastases form and where anti-tumoral immunity develops. Despite being the most potent antigen-presenting cells, dendritic cells (DCs) located in a nodal tissue can both promote or suppress immune response against cancer in SLNs. METHODS: In SLNs excisions obtained from 123 invasive BC patients, we performed immunohistochemistry (IHC) for CD1a, CD1c, DC-LAMP, and DC-SIGN to identify different DCs populations. Then we investigated the numbers of DCs subsets in tumor-free, micrometastatic, and macrometastatic SLNs with the use of a light microscope. RESULTS: We observed that CD1c+ and DC-SIGN+ DCs were more numerous in SLNs with a larger tumor size. More abundant intratumoral DC-LAMP+ population was related to a higher number of metastatic lymph nodes. Conversely, more abundant CD1a+ DCs were associated with a decreasing nodal burden in SLNs and a lower number of involved lymph nodes. Moreover, densities of the investigated DC populations differed with respect to tumor grade, HER2 overexpression, hormone receptor status, and histologic type of BC. CONCLUSIONS: According to their subtype, DCs are associated with either lower or higher nodal burden in SLNs from invasive BC patients. These relationships appear to be dependent not only on the maturation state of DCs but also on the histological and biological characteristics of the tumor.

show abstract

“…Thus, immature DCs act as sentinels against invading pathogens and as tissue scavengers, capturing apoptotic and necrotic cells [57]. Accordingly, immature DCs are essential for inducing and maintaining immune tolerance [58]. DCs internalize cell apoptosis and the loss of critical details in polyps, such as tissue turnover.…”

Section: The Role Of Gut Microbiota In Dysbiosis and Crcmentioning

confidence: 99%

Interaction between Gut Microbiota and Dendritic Cells in Colorectal Cancer

Zaher,

Basingab

2023

Biomedicines

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a malignancy that manifests in serial stages and has been observed to have an escalating incidence in modern societies, causing a significant global health problem. The development of CRC is influenced by various exogenous factors, including lifestyle, diet, nutrition, environment, and microbiota, that can affect host cells, including immune cells. Various immune dysfunctions have been recognized in patients with CRC at different stages of this disease. The signature of microbiota in the development of CRC—inflammation related to obesity, diet, and reactive host cells, such as dendritic cells (DCs)—has been highlighted by many studies. This study focuses on DCs, the primary cellular mediators linking innate and adaptive immune responses against cancer. In addition, this review focuses on the role of microbiota in dysbiosis and how it affects DCs and, in turn, the immune response and progression of CRC by stimulating different sets of T cells. Additionally, DCs’ role in protecting this delicate balance is examined. This is to determine how gene yields of commensal microbiota may be critical in restoring this balance when disrupted. The stages of the disease and major checkpoints are discussed, as well as the role of the C-type lectin receptor of immature DCs pattern recognition receptor in CRC. Finally, based on a thorough examination of worldwide clinical studies and recent advancements in cancer immunotherapy, it is recommended that innovative approaches that integrate DC vaccination strategies with checkpoint inhibitors be considered. This approach holds great promise for improving CRC management.

show abstract

Differentiation of human dendritic cell subsets for immune tolerance induction

Cited by 15 publications

References 30 publications

Everolimus-Induced Immune Effects after Heart Transplantation: A Possible Tool for Clinicians to Monitor Patients at Risk for Transplant Rejection

Everolimus-Induced Immune Effects after Heart Transplantation: A Possible Tool for Clinicians to Monitor Patients at Risk for Transplant Rejection

Presence of Dendritic Cell Subsets in Sentinel Nodes of Breast Cancer Patients Is Related to Nodal Burden

Interaction between Gut Microbiota and Dendritic Cells in Colorectal Cancer

Contact Info

Product

Resources

About